An association between increased breast cancer proliferation and poor outcome in response to endocrine therapies is clearly apparent from studies measuring both individual markers of proliferation (e.g. Ki67) and gene signatures associated with reduced survival [10], [40]–[42]. Here, MKI67 is linked to breast cancer.